ELISA Kit for Interleukin 1 Receptor Antagonist (IL1RA)

IL1RN; IL1-RA; ICIL1RA; IL1ra3; IL1F3; IRAP;IL-1RA; Interleukin-1 Family Member 3; IL1 inhibitor; Anakinra

Specificity

This assay has high sensitivity and excellent specificity for detection of Interleukin 1 Receptor Antagonist (IL1RA).
No significant cross-reactivity or interference between Interleukin 1 Receptor Antagonist (IL1RA) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Interleukin 1 Receptor Antagonist (IL1RA) and the recovery rates were calculated by comparing the measured value to the expected amount of Interleukin 1 Receptor Antagonist (IL1RA) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 78-98 95
EDTA plasma(n=5) 83-97 86
heparin plasma(n=5) 83-90 86

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Interleukin 1 Receptor Antagonist (IL1RA) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Interleukin 1 Receptor Antagonist (IL1RA) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Interleukin 1 Receptor Antagonist (IL1RA) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 83-90% 78-92% 94-101% 88-96%
EDTA plasma(n=5) 82-92% 88-95% 84-103% 79-105%
heparin plasma(n=5) 91-101% 96-104% 90-101% 88-95%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
TMB Substrate 1×9mL Stop Solution 1×6mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
8. Add 50µL Stop Solution. Read at 450nm immediately.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
The Veterinary Journal Mucosal imbalance of interleukin-1β and interleukin-1 receptor antagonist in canine inflammatory bowel disease ScienceDirect: S1090023312000962
Daily quercetin supplementation over a period of two weeks results in a moderate accumulation of total plasma flavonols in horses Researchgate:Source
Journal of Equine Veterinary Science Synovial Fluid and Serum Concentrations of Interleukin-1 Receptor Antagonist and Interleukin-1 Science: Article
Journal of Equine Veterinary Science A Two-Week Quercetin Supplementation in Horses Results in Moderate Accumulation of Plasma Flavonol Concentrations Science: Article
Scientific publications in peer reviewed journals Evidence-based review of efficacy and adverse effects of joint medication and evaluation of synovial fluid and serum markers for osteoarthritis in the horse receive:101658
Multiple Sclerosis and Related Disorders Interleukin 1 receptor antagonist and 2′-5′-oligoadenylate synthetase-like molecules as novel biomarkers for multiple sclerosis patients in Bahrain pubmed:29141788
Advances in Medical Sciences A similar pro/anti-inflammatory cytokine balance is present in the airways of competitive athletes and non-exercising asthmatics pubmed:28822267
Archives of Medical Research Winter ambient training conditions are associated with increased bronchial hyperreactivity and with shifts in serum innate immunity proteins in young … Pubmed:29379533
Journal of Veterinary Internal Medicine Effect of interleukin‐1β on occludin mRNA expression in the duodenal and colonic mucosa of dogs with inflammatory bowel disease Pubmed:29572935
Frontiers in Pharmacology M10, a Myricetin-3-ObD-Lactose Sodium Salt, Prevents Ulcerative Colitis Through Inhibiting Necroptosis in Mice Pubmed: 33041798
Catalog No. Related products for research use of Equus caballus; Equine (Horse) Organism species Applications (RESEARCH USE ONLY!)
RPA223Eq01 Recombinant Interleukin 1 Receptor Antagonist (IL1RA) Positive Control; Immunogen; SDS-PAGE; WB.
PAA223Eq01 Polyclonal Antibody to Interleukin 1 Receptor Antagonist (IL1RA) WB; IHC; ICC; IP.
MAA223Eq21 Monoclonal Antibody to Interleukin 1 Receptor Antagonist (IL1RA) WB; IHC; ICC; IP.
SEA223Eq ELISA Kit for Interleukin 1 Receptor Antagonist (IL1RA) Enzyme-linked immunosorbent assay for Antigen Detection.
LMA223Eq Multiplex Assay Kit for Interleukin 1 Receptor Antagonist (IL1RA) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.